A recent New England Journal of Medicine article reported on the results of the ARISTOTLE trial comparing the effectiveness of apixaban and warfarin for atrial fibrillation stroke prevention. Apixaban was shown to be superior to warfarin in preventing afib strokes. Learn more about the results of this trial at: Apixaban Superior to Warfarin for Atrial …
Read More
The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
In this important video interview at Venice Arrhythmias, Professor Gregory Lip discusses the importance of the CHA2DS2-VASc scoring tool for predicting atrial fibrillation stroke risk and why aspirin is not appropriate for preventing strokes. Watch the video at: Professor Gregory Lip Discusses CHA2DS2-VASc Tool for Predicting Stroke Risk in Atrial Fibrillation — Video
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
StopAfib.org is among a group of experts calling today for urgent action to prevent an atrial fibrillation stroke crisis in Latin America. Action for Stroke Prevention, a group of health experts from across the globe, is launching a new report, How Can We Avoid a Stroke Crisis in Latin America?, at the International Society for …
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
A brand new tool, Atrial Fibrillation in Primary Care (AFIP), was just released at the European Society of Cardiology meeting in Paris. This tool may be useful for afib patients and their caregivers, especially those who are newly-diagnosed with atrial fibrillation, in working with doctors. Two members of the StopAfib.org Global Medical Advisory Board are …
Read More
As a patient, you probably see lots of hype-filled reports about various drugs. After a drug is approved, there’s an inevitable blitz of negative publicity which often scares people away from important new solutions that could help them. There has been so much news lately about Multaq (dronedarone), the drug designed to provide the benefits …
Read More
The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed …
Read More
When the leading man in her life was diagnosed with atrial fibrillation (afib), actress Susan Lucci jumped into action and pledged to learn everything she could about his condition. Now she and her husband, Helmut Huber, ask you to join them in taking the Facing AFib Pledge to learn more about atrial fibrillation, partner with …
Read More